StockData

Biomerica vs Insight Molecular Diagnostics

BMRA and IMDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BMRA and IMDX compare

Insight Molecular Diagnostics is the larger company, worth 10 times as much as Biomerica ($60.9M against $6.1M).

Biomerica grew revenue faster over the last twelve months (−11.2% versus −60.8% for Insight Molecular Diagnostics).

Biomerica keeps more of each dollar of sales as profit, with a net margin of −115% compared with −2956% at Insight Molecular Diagnostics.

Biomerica scores higher on the StockData Score (8 against 7 for Insight Molecular Diagnostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBMRAIMDX
Size and price
Market cap$6.1M$60.9M
Share price$1.32$1.86
Change, 1 year−47.2%−76.3%
Change, 5 years−96.7%−96.1%
Beta (5Y)0.842.60
Employees1758
StockData Score
Total score8 (better)7
Valuation score3 (better)0
Growth score01 (better)
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S1.4× (better)36.4×
P/B1.7×–
FCF yield–−50.9%
Fair value$2.49–
Margin of safety47.0%–
Growth
Revenue growth (TTM)−11.2% (better)−60.8%
Revenue growth, 5Y average−9.2%27.2% (better)
Profitability
Gross margin0.90%48.3% (better)
Operating margin−125% (better)−3012%
Net margin−115% (better)−2956%
FCF margin–−1856%
Return on equity−114%–
Return on invested capital−284%–
Financial health
Debt / equity0.00–
Current ratio1.912.00 (better)
Altman Z-score−10.57 (better)−24.24
Piotroski F-score44
Dividends and buybacks
Buyback yield−52.2%−42.8% (better)
Shareholder yield−52.2%−42.8% (better)
Ownership
Held by institutions2.7%56.4%
Held by insiders27.4%81.6%
Insider net buying, 12 months$158K$5.7M (better)
Short interest, % of float0.37%17.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.